Market Overview The global HDAC inhibitor market is experiencing growth driven by epigenetic drug interest, cancer treatment focus, and disease understanding advancement. The HDAC inhibitor market is projected to exceed USD 2.8 billion through 2030, fueled by HDAC-driven disease prevalence, drug development pipeline, and clinical validation. HDAC inhibitors represent epigenetic therapy...